To Be or Not To Be Vaccinated: That Is a Question in Myasthenia Gravis

Myasthenia gravis (MG) is an autoimmune disease characterized by muscle weakness and abnormal fatigability due to the antibodies against postsynaptic receptors. Despite the individual discrepancy, patients with MG share common muscle weakness, autoimmune dysfunction, and immunosuppressive treatment, which predispose them to infections that can trigger or exacerbate MG. Vaccination, as a mainstay of prophylaxis, is a major management strategy. However, the past years have seen growth in vaccine hesitancy, owing to safety and efficacy concerns. Ironically, vaccines, serving as an essential and effective means of defense, may induce similar immune cross-reactivity to what they are meant to prevent. Herein, we outline the progress in vaccination, review the current status, and postulate the clinical association among MG, vaccination, and immunosuppression. We also address safety and efficacy concerns of vaccination in MG, in relation to COVID-19. Since only a handful of studies have reported vaccination in individuals with MG, we further review the current clinical studies and guidelines in rheumatic diseases. Overall, our reviews offer a reference to guide future vaccine clinical decision-making and improve the management of MG patients.
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research

Related Links:

The $335.8 million, 182,800-square-foot structure is the first start-to-finish UCSF construction project since the start of the Covid-19 pandemic, with the clinical building opening in 2024.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
Just griping about the lack of oversight &to rush things out ASAP without much thought or consideration on actual execution and logistics of such recommended/allowed updates on mixing and matching vaccines. Is anyone else feel like things are getting out of hand on a retail level? I mean, at a 24 hour store, it does not help that people can schedule appointments online for ridiculous times like 1am, 2am, 5am, etc. Zero though was put into consideration in regards to waste management... Read more
Source: Student Doctor Network - Category: Universities & Medical Training Authors: Tags: Pharmacy Source Type: forums
The CDC is urging parents and guardians to vaccinate children aged 5 to 11 against COVID-19 once the shot is fully approved.WebMD Health News
Source: Medscape Internal Medicine Headlines - Category: Internal Medicine Tags: Infectious Diseases News Source Type: news
At least 59,000 meatpacking workers caught COVID-19 and 269 workers died last year, which is significantly more than previously thought, according to a new US House report released Wednesday.Associated Press
Source: Medscape FamilyMedicine Headlines - Category: Primary Care Tags: Infectious Diseases News Source Type: news
Conclusion: Our systematic review indicated the potential of the COVID-19 virus to trigger a myriad of autoimmune and rheumatic manifestations, which should be considered amid global efforts to combat COVID-19.
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
As effective vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerge, it is important to have timely real-word data that guides immunization prioritization for our patients and especially possibly more vulnerable neuromuscular populations [1]. Recent data have shown that patients with chronic autoimmune neuromuscular disorders who are on immunosuppression were more likely to require hospitalization with Coronavirus Disease 2019 (COVID-19) [2]. Similarly, recent preliminary data published from the COVID-19 Associated Risks and Effects in Myasthenia Gravis (CARE-MG) registry, demonstrated a morta...
Source: Journal of the Neurological Sciences - Category: Neurology Authors: Tags: Letter to the Editor Source Type: research
RARITAN, N.J., November 5, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today more than 35 company-sponsored studies, including 10 oral presentations, will be featured at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition taking place virtually December 5-8, 2020.In multiple myeloma, highlights include Phase 1b/2 results for the B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR-T) therapy ciltacabtagene autoleucel (cilta-cel); new and updated data for the anti-CD38 monoclonal antibody DARZALEX® (daratumumab) and the subcutaneo...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
ConclusionsLack of availability of sound scientific knowledge inevitably lead unreliable news to spread over the population, preventing people to disentangle them form reliable information. Even if additional studies are needed to replicate and strengthen our results, these findings represent initial evidence to derive recommendations based on actual data for subjects with autoimmune diseases.
Source: Autoimmunity Highlights - Category: Allergy & Immunology Source Type: research
Myasthenia gravis (MG), an autoimmune neuromuscular disorder, may be a risk factor for severe COVID-19. We conducted an observational retrospective study with 15 consecutive adult MG patients admitted with COVID-19 at four hospitals in São Paulo, Brazil. Most patients with MG hospitalized for COVID-19 had severe courses of the disease: 87% were admitted in the intensive care unit, 73% needed mechanical ventilation, and 30% died. Immunoglobulin use and the plasma exchange procedure were safe. Immunosuppressive therapy seems to be associated with better outcomes, as it might play a protective role.
Source: Frontiers in Neurology - Category: Neurology Source Type: research
NEW BRUNSWICK, N.J., August 19, 2020 – Johnson &Johnson (NYSE:JNJ) today announced it has entered into a definitive agreement to acquire Momenta Pharmaceuticals, Inc. (Momenta), a company that discovers and develops novel therapies for immune-mediated diseases, in an all cash transaction for approximately $6.5 billion. This acquisition provides an opportunity for the Janssen Pharmaceutical Companies of Johnson &Johnson to broaden its leadership in immune-mediated diseases and drive further growth through expansion into autoantibody-driven disease. The transaction will include full global rights to nipocalimab...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Our Company Source Type: news
More News: Allergy & Immunology | Autoimmune Disease | COVID-19 | Myasthenia Gravis | Rheumatology | Study | Vaccines